Acrodose™ PL System for Pre-storage Pooling and Testing of Leukoreduced Whole Blood Derived Platelets

Hear directly from Pall customers using the Acrodose PL system. View our customer presentations with full audio/video:

AABB 2008 Industry Workshops
AABB 2007 Industry Workshops
AABB 2006 Industry Workshops
AABB 2005 Industry Workshops

One Approach: Using the Acrodose™ PL SystemFiltering Platelet Concentrates with the Leukotrap RC PL or PL Systems

• Leukoreduction  - Leukotrap RC PL and PL Systems are the only closed systems capable of producing leukoreduced CP2D whole blood platelets designed to work with the Acrodose PL System
• Pooling and Storing - The Acrodose PL System provides pre-storage pooling of leukoreduced whole blood-derived platelets.
• Bacteria Detection and Data Management - Pall eBDS* provides unsurpassed sensitivity and specificity in bacteria detection with minimal platelet loss. Pall Data captures the ouput from Pall eBDS and allows the information to be queried into a user-defined report.

*Customer may use an alternative market-cleared bacteria detection system.

Another Approach: Using the Acrodose™ PLus System
Filtering the Platelet Pool with the Acrodose PL Leukocyte Reduction Filter

• Collection- Produce non-leukoreduced whole blood platelets from either:
  • Pall collection systems, such as the Leukotrap RC System with RC2D Filter, or
  • Any collection system using CPD anticoagulant
• Bacteria Detection and Data Management - Pall eBDS allows for detection of bacteria in the prefiltered, non-leukoreduced pool, providing the maximum shelf life of the final platelet. Pall Data captures the ouput from Pall eBDS and allows the information to be queried into a user-defined report.
• Leukoreduction, Pooling and Storing - The Acrodose PLus System provides closed-system prestorage filtration of non-leukoreduced CPD or CP2D whole blood platelets – resulting in a pool of leukoreduced whole blood platelets.

An Acrodose^SM Platelet represents a “transfusion ready” platelet for the hospital that is leukoreduced, ABO matched, pooled and  bacteria tested. It enhances patient safety with culture-based bacteria testing for whole blood derived platelets. It also lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital. Read more...

View Components and Specifications for all Acrodose Systems.

• Platelets Likely Lose Efficacy When Stored From 5 to 7 Days
• Pool and Store Platelets – Augmenting Quality Platelet Supply To Meet Transfusion Requirements
• Bacterial Detection and Extended Platelet Storage: The Next Step Forward (Transfusion, December 2005)

Customers who use Pall blood products can access up-to-date training and implementation support for compliance with appropriate regulatory guidelines. For details, go to our Training and Education Section.

Using a platform of complementary products, blood collection facilities are able to produce a therapeutic dose of platelets that are pooled, leukoreduced, ABO matched, and bacteria tested with culture based detection methods – in other words, an Acrodose Platelet. Read more about: 

• Collecting and Processing: Leukotrap® RC PL and Leukotrap PL Systems 
• Pooling and Storing: Acrodose™ System
• Bacteria Detection and Management: Pall eBDS and Pall Data

For the full story, go to A New Platform for Platelet Transfusion Safety.

Maximizing benefits from existing resources is something many organizations are looking into in the face of the current economic climate. Better utilization of resources makes good ecological sense, and good business sense. Utilizing all three components from whole blood can reduce your ecological footprint, as well as improve your business model.

Every day, your facility must collect manual WB donations to address local blood demand. You can maximize the value of these manual WB donations to obtain the platelets you need while meeting your daily demand.

According to the 2007 National Blood Collection and Utilization Survey most platelets obtained from WB collections were typically discarded- as only 2.4 million WB units were processed into platelets out of the 14 million units of WB produced. This may have been in part due to the concern for patient safety. The advent of Acrodose Systems, that produces a therapeutic dose of platelets (Acrodose Platelets), renders this prudent but wasteful practice unnecessary- setting a new standard of care for WB platelets, while making use of a valuable resource.

If all of these WB collections were processed into platelets, it would likely meet all of the platelet needs in the US, and result in an estimated annual savings of over $275M.*

How do we arrive at these calculations? 

• First, from the 2007 National Blood Collection and Utilization Survey, platelet needs in the US are estimated at 2.3M doses: 1.823M apheresis + (2.396M PC's / 5 PC's per dose) = 2.3M platelets doses (US)
• Next, the estimated annual savings are calculated by again referring to the 2007 Blood Survey and finding that the average price for an apheresis platelet is $538.72. The average price for an individual whole blood derived platelet concentrate is $84.25.
• Calculations:
  • Pooled PC's= $84.25 x 5 unit pool = $421.25
  • Estimated savings per platelet dose = $117.47
  • 14M WB collections -2.3M PC units = 11.7M available PC's = 2.34M platelet doses

*Savings: 2.34M additional platelet doses x $117.47 estimated savings = $275M estimated annual savings (US)